Protagonist Therapeutics (PTGX) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free PTGX Stock Alerts $31.65 +0.18 (+0.57%) (As of 10:33 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 4:44 PM | finance.yahoo.comProtagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 CongressMay 13 at 8:55 PM | marketbeat.comGratus Capital LLC Has $9.12 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Gratus Capital LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 397,571 shares of the comMay 13 at 1:50 AM | americanbankingnews.comHC Wainwright Analysts Reduce Earnings Estimates for Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 11, 2024 | americanbankingnews.comProtagonist Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.69) Per Share, HC Wainwright Forecasts (NASDAQ:PTGX)May 10, 2024 | marketbeat.comAnalysts Offer Predictions for Protagonist Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:PTGX)Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Protagonist Therapeutics in a research note issued on Thursday, May 9th. HC Wainwright analyst D. Tsao anticipates that the company will pMay 10, 2024 | americanbankingnews.comJMP Securities Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $45.00May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical TrialsMay 9, 2024 | marketbeat.comProtagonist Therapeutics' (PTGX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $38.00 price target on shares of Protagonist Therapeutics in a report on Thursday.May 8, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $25.79Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $25.79May 8, 2024 | markets.businessinsider.comProtagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising PipelineMay 8, 2024 | investorplace.comPTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | chron.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | finance.yahoo.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic CollaborationsApril 29, 2024 | finance.yahoo.comWe Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) SoonApril 26, 2024 | finance.yahoo.comProtagonist Therapeutics, Inc. (PTGX)April 20, 2024 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 SharesApril 20, 2024 | marketbeat.comInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells 1,234 Shares of StockProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 1,234 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the transaction, the chief financial officer now directly owns 37,163 shares in the company, valued at approximately $933,162.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.April 18, 2024 | marketbeat.comReadystate Asset Management LP Has $1.31 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Readystate Asset Management LP trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 69.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,206 shares of the company's stock after sellinApril 9, 2024 | marketbeat.comVanguard Group Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Vanguard Group Inc. increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,228,394 shares of the company's stock after buying an additioApril 3, 2024 | insidertrades.comInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 25,000 Shares of StockApril 3, 2024 | finance.yahoo.comProtagonist Therapeutics Inc CEO Sells 25,000 SharesApril 1, 2024 | finance.yahoo.comShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%March 27, 2024 | markets.businessinsider.comProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic PartnershipsMarch 18, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with TakedaMarch 18, 2024 | marketbeat.comWalleye Capital LLC Grows Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Walleye Capital LLC raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 209.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,816 shares of the company's stock after purchasingMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 15.000 callMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 30.000 putMarch 12, 2024 | bizjournals.comThe People's Market owner snaps up former Protagonist space in heart of NoDa for barMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113March 11, 2024 | markets.businessinsider.comStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial OutlookMarch 9, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $11.68 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Adage Capital Partners GP L.L.C. lessened its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 45.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 700,000 shares of the company's stock aftMarch 8, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Kennedy Capital Management LLCKennedy Capital Management LLC decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 20.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,534 shares of the company'sMarch 7, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Purchases New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Schonfeld Strategic Advisors LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 154,098 shares of the company's stock, valued at approximatelyMarch 3, 2024 | finance.yahoo.comThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This YearMarch 2, 2024 | finance.yahoo.comEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their EstimatesMarch 1, 2024 | finance.yahoo.comProtagonist Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | marketbeat.com683 Capital Management LLC Sells 81,216 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)683 Capital Management LLC cut its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 10.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 732,784 shares of the company's stock after selling 81,216 shares during theMarch 1, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Forecasted to Post FY2024 Earnings of $2.35 Per ShareProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Analysts at Capital One Financial increased their FY2024 EPS estimates for shares of Protagonist Therapeutics in a report issued on Wednesday, February 28th. Capital One Financial analyst T. Chiang now anticipates that the company willFebruary 29, 2024 | finance.yahoo.comWe're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash BurnFebruary 29, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 23,931 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Connor Clark & Lunn Investment Management Ltd. trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 14.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139,494 shares of the compFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic PartnershipsFebruary 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)February 28, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High on Earnings BeatProtagonist Therapeutics (NASDAQ:PTGX) Sets New 1-Year High Following Earnings BeatFebruary 28, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Releases Earnings Results, Beats Estimates By $0.39 EPSProtagonist Therapeutics (NASDAQ:PTGX - Get Free Report) posted its earnings results on Tuesday. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.39. The business had revenue of $60.00 million during the quarter, compared to analyst estimates of $60.00 million.February 28, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) PT Raised to $37.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their price objective on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the stock an "overweight" rating in a research note on Wednesday.February 28, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday.February 28, 2024 | marketbeat.comAlgert Global LLC Purchases 45,600 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Algert Global LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 167.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,830 shares of the company's stock after acquiFebruary 26, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Makes New $1.47 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Healthcare of Ontario Pension Plan Trust Fund bought a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 88,000 shares of the companFebruary 25, 2024 | seekingalpha.comProtagonist Therapeutics: Why I Remain On Sidelines Despite Obvious PromiseFebruary 23, 2024 | marketbeat.comCitigroup Inc. Grows Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Citigroup Inc. boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 37.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 147,828 shares of the company's stock after acquiring Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. PTGX Media Mentions By Week PTGX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.690.55▲Average Medical News Sentiment PTGX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼163▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Harmony Biosciences News Schrödinger News Structure Therapeutics News Ardelyx News NewAmsterdam Pharma News Syndax Pharmaceuticals News Edgewise Therapeutics News Kura Oncology News Supernus Pharmaceuticals News Taro Pharmaceutical Industries News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldDoes this make you sick?Allegiance GoldTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
